Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.05 -0.61% 8.20 2,382,166 16:35:15
Bid Price Offer Price High Price Low Price Open Price
8.20 8.30 8.40 8.25 8.25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -3.17 -2.10 23
Last Trade Time Trade Type Trade Size Trade Price Currency
16:42:27 O 159,090 8.20 GBX

Evgen Pharma (EVG) Latest News

More Evgen Pharma News
Evgen Pharma Investors    Evgen Pharma Takeover Rumours

Evgen Pharma (EVG) Discussions and Chat

Evgen Pharma (EVG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Evgen Pharma trades in real-time

Evgen Pharma (EVG) Top Chat Posts

Evgen Pharma Daily Update: Evgen Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 8.25p.
Evgen Pharma Plc has a 4 week average price of 8.15p and a 12 week average price of 8.10p.
The 1 year high share price is 16.83p while the 1 year low share price is currently 2.75p.
There are currently 274,888,117 shares in issue and the average daily traded volume is 1,023,691 shares. The market capitalisation of Evgen Pharma Plc is £22,540,825.59.
moneymunch: 3 March 2021 Evgen Pharma plc ("Evgen Pharma" or "the Company") Result of Open Offer Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, is pleased to announce the results of its Open Offer. On 2 February 2021, Evgen announced its intention to raise gross proceeds of up to £11 million by way of a Placing and Open Offer, all at an issue price of 8 pence per New Ordinary Share. A total of 137,490,676 New Ordinary Shares will be issued at the Issue Price (subject to the conditions noted below), of which, 12,490,676 New Ordinary Shares will be issued pursuant to the Open Offer. This brings the gross proceeds of the Fundraising to approximately £11 million before expenses. The Open Offer closed for acceptances at 11.00 a.m. yesterday. The Company has received valid acceptances from Qualifying Shareholders in respect of their Basic Entitlements in respect of 5,389,931 New Ordinary Shares, representing approximately 43 per cent. of the Open Offer Shares. In addition, the Company has received applications from Qualifying Shareholders under the Excess Application Facility in respect of 14,359,431 New Ordinary Shares, representing a total over-subscription of approximately 58 per cent. of the available Open Offer Shares. Accordingly, Qualifying Shareholders who have validly applied for Open Offer Shares will receive their full Basic Entitlements. As applications under the Excess Application Facility cannot be satisfied in full, applications for New Ordinary Shares under the Excess Application Facility will be scaled back in accordance with the terms set out in the Circular. General Meeting The Fundraising remains conditional on the approval by Shareholders of the Resolutions at the Company's General Meeting to be held at 10:00 a.m. today (or any adjournment thereof), the satisfaction of certain conditions in the Placing Agreement and Admission of the New Ordinary Shares to trading on AIM occurring at or before 8.00 a.m. on 4 March 2021 (or such later date as the Company and finnCap may agree, being not later than 8.00 a.m. on 18 March 2021). The Company will announce the results of the General Meeting as soon as practicable after the meeting concludes.
moneymunch: " Two of the most recent examples are the placings by Evgen Pharma plc, the clinical stage company focussed on the treatment of cancer and inflammation, and Synairgen plc, the respiratory drug discovery and development company, both listed on AIM. These biotechs are suddenly in the enviable position of having to choose between scaling back allocations or only accepting the money on the table from specific investors." ......................... Booming biotech sector allows for choices over investment Out-Law Analysis | 23 Feb 2021 There has been a growing interest in biotech companies since the onset of the Covid-19 pandemic. Over $13 billion was invested worldwide in biotech companies in 2020 alone. As a result of this increased flow of capital into the sector, biotech companies are becoming more selective about the investors with whom they choose to partner, taking a longer term view than might have previously been the case in a sector in which the cash burn rate from R&D is well known. This theme of the discerning biotech was a central focus at the recent LSX World Congress. This annual event brings together life sciences industry executives – from those involved in start-ups to those leading the world's biggest pharmaceutical companies – and the investment community. Investors without any particular insights into the sector are naturally drawn to the human stories behind products, and in the biotech sector there is no shortage of narrative that companies can play on Widening interest in the sector Specialist healthcare investors know that investment in biotechs requires a long-term view, recognising that it can take years of research and substantial capital for companies to develop new products and deliver meaningful returns on their investment. The risk involved in picking the correct companies to invest in, and at the right time, has meant that the sector has been the domain of specialist investors who understand the science. This changed with the onset of the pandemic when a growing number of investors recognised that, with so many biotechs pivoting ongoing trials to test whether existing products in development had application to coronavirus, any good news from those companies could lead to substantial bumps in share prices, often in excess of 100%. The potential size of these returns suddenly outweighed the risk that had previously made non-specialist healthcare investors wary of the sector. Moreover, driven by the turmoil in sectors such as retail, hospitality and airlines, companies in the life sciences sector felt like a relatively safe place for institutions to invest. A McKinsey study highlighted at the LSX World Congress indicated that, while biotechs listed on the public markets did experience a downturn in share prices in spring 2020, that downturn was short-lived, with average share prices rising 39% in Europe, 37% in the US and 106% in China between 1 January 2020 and 19 January 2021. As a result, much of the recent investment interest in the biotech sector has been from non-specialist investors whose attention has been drawn by the sector's resilience to the Covid-19 pandemic. Industry success stories also help to raise the profile of the sector. The rise to international prominence of German biotech BioNTech, following its partnership with Pfizer and development of a Covid-19 vaccine, is an example of the attention the sector is gaining for its innovation and real-life impact. Investors without any particular insights into the sector are also naturally drawn to the human stories behind products, and in the biotech sector there is no shortage of narrative that companies can play on. For instance, with recent advances in the use of data and technology, companies have been able to focus their innovation around a 'patient-centric' approach to medicine, with personalised medicine, including cell and gene therapies, which show such promise in the treatment of rare diseases, coming to prominence. Increasingly, the 'story' behind, or theoretic potential of, a product is more important than the data behind it, particularly for non-specialist healthcare investors. This growing interest in the sector has resulted in many of the equity fundraisings conducted by publicly traded biotechs being significantly over-subscribed, as more investors have sought to put their faith in biotech stocks. Two of the most recent examples are the placings by Evgen Pharma plc, the clinical stage company focussed on the treatment of cancer and inflammation, and Synairgen plc, the respiratory drug discovery and development company, both listed on AIM. These biotechs are suddenly in the enviable position of having to choose between scaling back allocations or only accepting the money on the table from specific investors. In addition, the increased flow of cash into the sector is prompting competition between investors about the timing of their investment, with an increasing number prepared to invest earlier in the life cycle of a biotech, often at the 'Series A' funding round. Certain funds that traditionally have been focussed on public markets are re-assessing this focus and looking more closely at early stage biotechs. Marshall Wace and Third Point are two big hedge funds that are currently raising money – $400m and $300m, respectively – to invest in privately held healthcare companies that are between six months and two years out from IPO, with a view to holding on to those companies after they list. While the recent returns on many investments in listed biotechs is impressive, some investors are recognising that even they can be dwarfed if they give their backing to the right company early enough in its development. Those investors know that the best value will come from investing early in a company at cheaper valuations, with the rewards coming if that company has a product approved. The risk/reward analysis has been tipped in favour of reward by the evident strength of biotechs over the last 12 months. hTtps://
moneymunch: Update on patient recruitment EVGEN PHARMA PLC Released 07:00:10 17 February 2021 RNS Number : 3128P Evgen Pharma PLC 17 February 2021               Evgen Pharma plc  ("Evgen" or the "Company")   Update on patient recruitment STAR COVID-19 trial exceeds 100 patients   Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces that as of 16 February, a total of 102 patients had been recruited and randomised to the STAR trial ("SFX-01 Treatment for Acute Respiratory infections").   This Phase II/III trial is a randomised, placebo-controlled trial, sponsored by the University of Dundee and funded by the UK charity LifeArc. It is investigating whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome ("ARDS") in patients with suspected COVID-19. Patients may be included in the study if they are infected with SARS-CoV-2 or another respiratory infections causing community-acquired pneumonia.   The trial design includes an assessment of safety and futility by a Data Safety and Monitoring Board ("DSMB") who will review unblinded data on the first 100 patients treated. In addition to the DSMB safety and futility assessment, Dundee University ("the Sponsor") has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy. This may lead to adjustments to the design of the trial for remaining patients, including in patient numbers, and possibly early termination for either safety, futility or alternatively, strong efficacy. It is expected that this initial data will be available during the second quarter of calendar 2021.   The Sponsor has also requested that the DSMB review data from the first 60 patients solely for safety and this process will be starting shortly. The outcome of this is expected to be available in early Q2 2021.   Completion of recruitment to the STAR trial is anticipated at the end of 2021/Q1 2022, assuming there are no substantial changes in the total patients to be recruited.    Dr Huw Jones, CEO of Evgen, commented: "We are pleased with the recruitment progress in this trial and would again like to thank Professor James Chalmers and his colleagues at Dundee for their considerable efforts in a very challenging clinical environment. Randomising over 100 patients is an important milestone in this trial and takes us a step closer to receiving the initial data from the study. We look forward to further updating the market as we progress through this important trial.''
moneymunch: There are currently over 25,000 patients in hospital and although the R numbers are dropping because of the lockdown, cases are still high and no doubt would increase again if and when the lockdown is relaxed , we also know that SFX-01's Covid recruitment process is now rapid, 9 patients as of 7/12/20, 56 patients as of 18/1/21 and 89 patients confirmed 1/2/21, and Prof Chalmers has also put the call out 19/1/21 for more trial sites to participate, whether or not this will include any international sites given his strong international network with other academics involved in respiratory desease, is yet to be seen. We also know that SFX-01's recruitment isn't reliant on paitients testing Covid positive, as it is focused on ARDS, a condition with very few effective treatments, and so no shortage of potential patients for SFX-01's recruitment over the next few months or so imho, during which time we could have multiple positive newsflow from the rest of the pipeline which could drive Evgen's share price to new highs. Exciting times for all invested with undoubted transformational UPside potential, with c£13m cash in the bank and a market cap of c£20m at a share price of 8p by first week of March...Fill ya Boots!!! Gla holders ;-) ................... There are about 200,000 cases of ARDS each year in the United States. ARDS is a serious disease. The chances of dying from this disease are around 30% to 50%. Those who survive will often have long hospital stays. hTtps:// ................... The Telegraph R number drops below 1 for first time since July 12 February 2021 • 6:59pm The reproduction number, or R value, of coronavirus has fallen below one for the first time since July and is now estimated to be between 0.7 and 0.9 across the UK. In a sign that lockdown restrictions are having an impact and the epidemic is shrinking, scientists advising the Government gave their most optimistic outlook for the R number since cases fell last summer. It comes as new data from the Office for National Statistics shows a drop in infections, with around one in 80 people in private households in England having Covid-19 between January 31 and February 6, the equivalent of 695,400 people. This is down from around one in 65 people for the period January 24 to 30. On February 9, the latest date for which figures are available, the number of patients in hospital with Covid-19 in the UK stood at 25,621. But while scientists advising the Government believe cases of Covid-19 are dropping at a decent pace across England, they have warned that infection levels remain high. Kevin McConway, Emeritus Professor of Applied Statistic from The Open University, said: “These revisions of the ranges for R and the growth rate are more good news, on top of the good news from the ONS Infection Survey earlier today." "But that doesn’t mean we can take the foot off the brake yet." .................. 19/1/21 James D Chalmers @ProfJDChalmers STAR-COVID is still looking for additional trial sites. Anyone interested please e-mail or direct message me. hTtp:// ..................... 11/11/20 Dr Huw Jones, Evgen CEO, commented: "We are pleased to see such progress on a potential vaccine against COVID-19. Recently ARDS has been heavily associated with COVID-19 as it affects the respiratory tract, but it is and will remain a condition in its own right long after we have beaten the pandemic and will continue to be a huge problem for patients. There is a considerable unmet need for effective treatments for ARDS and the outcome of our study will hopefully show how we can use SFX-01 in a serious respiratory condition regardless of the infective agent involved."
mesquida: Well you are right about one thing, moneymunch, the smart money IS flooding in, but the problem for us long term shareholders is that due to the shehanigans of FinnCap the money is flooding in when the stock price is at an artificially depressed level. The way in which this placing played out does not seem to bother you at all, you continue to bombard the board wih bullish references to Sulforaphane without ever mentioning the horrible dilution that we have just suffered. I suspect that you perhaps don't understand that ultimately the level of a share price will always be a function of the number of shares that are in issue. What perhaps you should focus on is that now we will be sharing the potential rewards of what could admittedly be a ground-breaking project with a host of FinnCap clients who have managed to climb aboard the train just as it is leaving the station. No, not for them the miserable wait and unrelenting share price underperformance that the rest of us have had to endure these past 5 years. No, these guys are coming in at just the right moment, and i cannot criticise them for that, but the fact is that the share price was engineered downwards these past 6 months ( during which time most other pharma stocks were going bonkers ) thus providing an opportunity for these guys to buy in at an unrealistically low price. And that my friend is why the placing was over subscribed. I do not know if you are in contact with the company, but if you are then you should ask them why they did not insist on a higher price for the placing once it was obvious that it was going to be well over-subscribed. But then again our Directors do not actually have much skin in the game, so dilution is probably not going to keep them awake at night. I have said it before and i will say it again, the prescence of FinnCap as a house broker is definitely a red flag.
moneymunch: Evgen Pharma raises funds to accelerate clinical and pre-clinical work 2021-02-02 16:05:00 The company said it has raised £10mln through a share placing and will aim to raise an additional £1mln through an open offer to qualifying shareholders      Evgen Pharma PLC (LON:EVG) said it has raised £10mln through a share placing that it said will be used to accelerate future clinical and current pre-clinical work across a range of projects. The AIM-listed firm said it had raised the funds through the placing of 125mln new shares at a price of 8p each, a 14.4% discount to its closing price on Monday, adding that it will also provide an opportunity for qualifying shareholders to subscribe for up to 12.49mln new shares at the placing price to raise an additional £1mln. WATCH: Evgen Pharma updates on the ‘STAR’ trial for Covid-19, Glioma research and key breast cancer drug Evgen said the proceeds of the fundraising will be used to fund further preclinical work for metastatic breast cancer (mBC), glioma and a further cancer indication yet to be announced, as well as potentially providing funds for a clinical trial in glioma patients. The firm said the cash is also intended to be used to complete the formulation and scale up manufacturing of its SFX-01 treatment for metastatic breast cancer, as well as complete all preparatory work to file an Investigational New Drug application in the US for the drug. Additionally, the money will also be put towards funding the company’s operations to mid-2023, which will include the hiring of a chief business officer and a chief scientific and medical officer. Meanwhile, Evgen said it is making “good progress” with patient recruitment for a Phase II/III randomised, placebo-controlled STAR-COVID 19 trial, which so far has recruited 89 patients. "This heavily oversubscribed fundraising is transformative for us and allows us to accelerate both our future clinical and current pre-clinical work dramatically, together with expanding our senior management team to support our growth”, Evgen chief executive Huw Jones said in a statement. “We are very pleased with recent progress of our work on SFX-01 and are most grateful for the support shown in this placing by existing shareholders. The Placing also brings a number of new, high quality shareholders to our register and we offer a warm welcome to them as we accelerate our progress in a range of cancers and acute respiratory distress", he added.
njb67: Wanobi I disagree. They do not need to raise monies straight away, they have 6 months or so grace period, and far better to raise monies once the investment story has progressed and this is hopefully reflected in a higher share price. Both IMM and SNG have taken the opportunity of a significant rise in their share price to tap the market for funds. Existing shareholders, including those who were gifted rather than bought shares, will face a lower level of dilution from a higher share price. You need to give away less of the future revenues of the business to secure the investment. love It is a fair point about directors investing their own money to buy stock. However, for many directors, a very significant proportion of their future personal wealth is effectively tied up in performance of the company so at a personal level putting more of the remaining eggs in the same basket may not be sensible financial planning.
njb67: mm 628 Which bit of my post 625 do you not understand? "I have followed this thread and have been looking at EVG for a number of months before buying shares yesterday. I plan to hold these until the company prospects are fully recognised in the share price (many multiples of the price today) or if the story changes and I do not believe the share is no longer significantly undervalued." I would sell out if I believed the share price was no longer significantly undervalued. I bought shares yesterday because I believe the company is significantly undervalued. I still hold those shares because my view has not changed, the company is significantly undervalued. If you are going to misrepresent my posts, then I will not waste my time engaging with you.
njb67: mm If that is directed at me, then no. I invest in companies that I think are substantially undervalued and then wait until the market catches up. Old fashioned value investment approach. I have followed this thread and have been looking at EVG for a number of months before buying shares yesterday. I plan to hold these until the company prospects are fully recognised in the share price (many multiples of the price today) or if the story changes and I do not believe the share is no longer significantly undervalued. I have neither the time, ability nor temperament to second guess short term share price movements. I am looking to buy pound coins for pennies rather than scalp a few percentage points here and there.
njb67: mm This is a small cap pharma with no revenue. At some point it will need to raise monies, it is inevitable. Unless some kind person gifts EVG the cash, then there will be dilution of existing shareholders. It is how this sector works. I do find the EVG use of "non-dilutive" unhelpful. While the intention may well be to enter an agreement that does not negatively impact the share price, they will be giving away a claim on the future revenues of the company in return for investment. Today shareholders own 100% of the future revenues of the pipeline. By giving away some of these revenues in return for investment, shareholders have been diluted. On timing, no sensible company will wait until their cash is about to run out before tapping the market, that would be irresponsible. I would expect a fund raise Q2-3, or should the share price rise substantially in the near term, so you are giving away less of the prospects of the business. As others have mentioned, a fund raise that sped the development of pipeline assets should net net be the most effective way to create shareholder value through the early commercialisation or sale of the assets.
Evgen Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210304 23:19:19